西南证券维持九洲药业买入评级：业绩延续高增长，CDMO业务持续加速

七印授权

52HU0J4904FTLZ6LGHWLJYFRZLRFTEWDQZGJ5GVKL1CCHX5JB4

2023-01-23 14:08:14

article

BF8BD8313645935CE41623EF3D709EEBEEFFDEF146567C2C5BB7EF324EF5BA48

zh-CN

4923CFCD2C90249044AAB7420DC1644D9EAE543A

13998406

02636d79fc7c7cc37b9cb348037eec28743d030e5d570d0d69837a3587bed31880

85f855430a3ebac01fcf7256f8f57f28c58b38aef8178fd9c6aa795d60d6026b767823c49cefa9c19dd4b12b322882535076af433ba42404b0c53e1b0e074ee91c

{"parameters":{"adaptation":"n","price":"100000"},"type":"cm"}

yuanben_63ce94ced139b6.07778401

原本认证

https://www.yuanben.io/article/18a567d9-4e14-4596-ac4b-8499d645d68b

{"author":"每日经济新闻","authorization_pub_key":"03040cbbeae1adf91c3efd7306d09c6005403a041f9b7405dac489d4f8126fef8c"}